ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 51 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $340,594 | -74.4% | 64,142 | -54.1% | 0.00% | – |
| Q2 2023 | $1,331,837 | +36.4% | 139,752 | +57.4% | 0.00% | – |
| Q1 2023 | $976,569 | -65.9% | 88,779 | -54.1% | 0.00% | -100.0% |
| Q4 2022 | $2,861,003 | +535.8% | 193,311 | +720.1% | 0.00% | – |
| Q3 2022 | $450,000 | +26.1% | 23,572 | +41.0% | 0.00% | – |
| Q2 2022 | $357,000 | -65.9% | 16,719 | -69.2% | 0.00% | – |
| Q1 2022 | $1,046,000 | -7.8% | 54,302 | -0.7% | 0.00% | – |
| Q4 2021 | $1,134,000 | +57.5% | 54,663 | +81.3% | 0.00% | – |
| Q3 2021 | $720,000 | +133.0% | 30,155 | +167.1% | 0.00% | – |
| Q2 2021 | $309,000 | -47.7% | 11,290 | -44.8% | 0.00% | – |
| Q1 2021 | $591,000 | +3183.3% | 20,446 | +3235.4% | 0.00% | – |
| Q3 2020 | $18,000 | -80.9% | 613 | -80.3% | 0.00% | – |
| Q2 2020 | $94,000 | -51.3% | 3,110 | -51.9% | 0.00% | – |
| Q1 2020 | $193,000 | – | 6,468 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |